. 2009 Nov;32(Suppl 2):S260–S265. doi: 10.2337/dc09-S319

Table 3.

Main outcomes in the APOLLO trial and the 4-T study

	APOLLO		4-T
	Target A1C ≤7% at 44 weeks		Target A1C ≤7% at 52 weeks
	Basal^*	Prandial^†	Basal^*	Prandial^†
A1C (%)
At baseline	8.73	8.67	8.40	8.60
At endpoint	6.98	6.80	7.60	7.20
Δ (baseline vs. endpoint)	−1.75	−1.87		−1.40
Responder rate (% patients achieving A1C target)
≤7.0%	57	69	28	49
≤6.5%	30	38	8	24
Responder rate (% patients achieving FBG target)	38	6
Insulin dose (IU/day) at end point	42	45	42	56
Treatment satisfaction score^‡ (Δ change from baseline)	+6.23	+2.74	±0	−0.02
Number of overall hypoglycemic events per patient-year	5.2	24.0 (×4.6)	2.3	12.0 (×5.2)
Change in body weight (Δ kg from baseline)	+3.0	+3.5	+1.9	+5.7

*Basal insulin: insulin glargine for APOLLO trial, insulin detemir for 4-T study.

†Prandial insulin: insulin lispro for APOLLO trial, insulin aspart for 4-T study.

‡Assessed by Diabetes Treatment Satisfaction Questionnaire scores (19) in the APOLLO trial and assessed by EuroQol 5-Dimension Self-Report Questionnaire scores (21) in the 4-T study.